Loading...
XTAI
1707
Market cap628mUSD
Jul 11, Last price  
124.00TWD
1D
1.22%
1Q
-6.42%
Jan 2017
-33.69%
Name

Grape King Bio Ltd

Chart & Performance

D1W1MN
P/E
12.68
P/S
1.65
EPS
9.78
Div Yield, %
5.56%
Shrs. gr., 5y
1.69%
Rev. gr., 5y
3.85%
Revenues
11.16b
+4.93%
1,489,681,0001,702,107,0002,112,457,0002,821,859,0003,282,274,0003,771,021,0004,611,719,0005,652,413,0006,282,859,0007,247,855,0009,185,021,0009,388,128,0009,183,321,0009,239,070,0009,168,195,0009,798,246,00010,391,231,00010,635,464,00011,160,005,000
Net income
1.45b
-0.30%
150,422,000180,871,000164,522,000379,341,000427,700,000473,062,000618,902,000835,762,000942,483,0001,051,652,0001,296,769,0001,351,941,0001,295,394,0001,938,566,0001,895,095,0001,947,989,0002,169,687,0001,452,728,0001,448,299,000
CFO
1.88b
-25.54%
468,842,000253,111,000434,852,000720,611,000683,894,000848,526,0001,121,257,0001,575,779,0001,701,422,0001,306,930,0002,803,128,0002,495,656,0002,417,429,0002,171,439,0002,719,190,0002,542,204,0002,990,437,0002,519,402,0001,875,912,000
Dividend
Jun 23, 20254.2 TWD/sh
Earnings
Aug 11, 2025

Profile

Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.
URL
https://www.grapeking.com.tw/
IPO date
Dec 20, 1982
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,160,005
4.93%
10,635,464
2.35%
10,391,231
6.05%
Cost of revenue
8,660,148
8,136,323
7,838,398
Unusual Expense (Income)
NOPBT
2,499,857
2,499,141
2,552,833
NOPBT Margin
22.40%
23.50%
24.57%
Operating Taxes
502,152
519,109
518,191
Tax Rate
20.09%
20.77%
20.30%
NOPAT
1,997,705
1,980,032
2,034,642
Net income
1,448,299
-0.30%
1,452,728
-33.04%
2,169,687
11.38%
Dividends
(1,022,148)
(1,022,148)
(903,638)
Dividend yield
4.60%
4.39%
3.61%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
53,948
56,560
46,943
Long-term debt
267,874
329,280
268,561
Deferred revenue
Other long-term liabilities
20,207
20,515
19,043
Net debt
(4,213,563)
(6,081,025)
(4,440,863)
Cash flow
Cash from operating activities
1,875,912
2,519,402
2,990,437
CAPEX
(626,706)
(587,179)
(502,469)
Cash from investing activities
(662,108)
(654,732)
(330,309)
Cash from financing activities
(1,717,384)
(1,708,931)
(1,628,551)
FCF
1,868,598
1,769,960
1,905,715
Balance
Cash
4,432,013
4,969,911
4,789,901
Long term investments
103,372
1,496,954
(33,534)
Excess cash
3,977,385
5,935,092
4,236,805
Stockholders' equity
7,221,299
8,833,146
8,285,152
Invested Capital
7,994,428
5,908,278
6,054,972
ROIC
28.74%
33.10%
32.07%
ROCE
20.74%
20.96%
24.64%
EV
Common stock shares outstanding
148,531
149,122
149,062
Price
149.50
-4.17%
156.00
-7.14%
168.00
5.00%
Market cap
22,205,395
-4.55%
23,263,032
-7.11%
25,042,416
5.47%
EV
19,726,828
18,833,643
22,172,854
EBITDA
3,013,341
2,958,904
3,002,471
EV/EBITDA
6.55
6.37
7.38
Interest
3,036
2,538
2,367
Interest/NOPBT
0.12%
0.10%
0.09%